Hint mode is switched on Switch off

Regeneron, ordinary share
US75886F1075, REGN, REGN-RM, RGO, REGN.P

Add a stock to WL
Regeneron, сountry — USA
No trading data
Data display in a chart | table
from
to
Source of information - PJSC "MOEX". Further disctribution of MOEX information is prohibited without prior consent with PJSC "MOEX".
Source of information - PJSC "MOEX". Further disctribution of MOEX information is prohibited without prior consent with PJSC "MOEX".
More than 2,500 records have been found, please specify your request
Latest data on

Latest quotes

Find Any Data on Any Bond in Just One Click

Full data on over 500,000 bonds and stocks worldwide

Powerful bond screener

Ratings from the top 3 global ratings agencies, plus over 70 local ones

Over 300 pricing sources from the OTC market and world stock exchanges

User-friendly and intuitive across multiple platforms

Get access

Issuer

Profile
Regeneron Pharmaceuticals, Inc. (Regeneron) is an integrated biopharmaceutical company, which discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. As of December 31, 2011, the Company had two marketed products: EYLEA ...
Regeneron Pharmaceuticals, Inc. (Regeneron) is an integrated biopharmaceutical company, which discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. As of December 31, 2011, the Company had two marketed products: EYLEA (aflibercept) Injection and ARCALYST (rilonacept) Injection for Subcutaneous Use. As of December 31, 2011, the Company had 13 product candidates in clinical development. Its Trap-based, late-stage programs are EYLEA, which is being developed for the treatment of additional serious eye diseases; ZALTRAP (aflibercept), known in the scientific literature as vascular endothelial growth factor (VEGF) trap, which is being developed in oncology in collaboration with Sanofi; and ARCALYST, which is being developed for the prevention of gout flares in patients initiating uric acid-lowering treatment.
  • Issuer
  • Full borrower / issuer name
    Regeneron Pharmaceuticals Inc
  • Industry
    Pharmaceutical Preparation and Biotechnology

Domestic and international bonds of the issuer

Holders

Registration is required to get access.